Cyclin-dependent kinase subunit 1 (Cks1) is a critical rate-limiting component of the Skp1-Cullin1-Skp2 (SCF Skp2 ) ubiquitin ligase that controls cell cycle inhibitor abundance. Cyclin-dependent kinase (Cdk) inhibitors (CKIs) regulate hematopoietic stem cell (HSC) self-renewal, regeneration after cytotoxic stress and tumor cell proliferation. We thus studied the role of Cks1 in HSC and in a prototypic stem cell disorder, chronic myeloid leukemia (CML). Cks1 transcript was highly expressed in Lin − Sca-1+Kit+ (LSK) HSC, and the loss resulted in accumulation of the SCF Skp2 /Cks1 substrates p21, p27, p57 and p130 particularly in CD150+ LSK cells. This accumulation correlated with decreased proliferation and accumulation of Cks1 −/− HSC, slower regeneration after stress and prolonged HSC quiescence. At the hematopoietic progenitor (HPC) level, loss of Cks1 sensitized towards apoptosis. In CML, Cks1 expression was increased, and treatment with the Abl kinase inhibitor, imatinib, reduced Cks1 expression. Also, we found that Cks1 is critical for Bcr-Abl-induced cytokine-independent clonogenic activity. In conclusion, our study presents a novel function of Cks1 in maintaining HSC/HPC homeostasis and shows that Cks1 is a possible target in therapies aimed at the SCF Skp2 /Cks1 complex that controls CKI abundance and cancer cell proliferation.
INTRODUCTION
Hematopoiesis involves a hierarchy of hematopoietic stem cells (HSCs), progenitor cells (HPCs) and mature blood cells. Regulation of the cell cycle has a key role during steady state and challenged blood production and also serves as a checkpoint towards uncontrolled cell proliferation that might lead to blood malignancies. In addition, as the vast majority of HSC are in a quiescent state, the regulation of their entry into the G1 and S phase in response to demand is a crucial step in hematopoiesis. [1] [2] [3] Cyclin/cyclin-dependent kinase (cyclin/Cdk) complexes and their inhibitors (CKI) are the major directing elements in cell cycle transition. The CIP/KIP family members p21 Cip (p21), p27 Kip1 (p27) and p57 Kip2 (p57) restrain entry into S phase by inhibiting the activity of the cyclin E-Cdk2 complex. 4 Mice deficient for cell cycle regulators display modest to severe phenotypes affecting different levels of the HSC/HPC hierarchy. 1, 5 The different CIP/KIP family members have both overlapping and unique roles in this process. For instance, p27 has been shown to be important for regulation of cell cycle activity of more committed HPC, but lack of p27 alone did not affect HSCs number or cycling. 6 Conditional deletion of p57 in hematopoietic cells demonstrated that p57 is a critical mediator of HSC quiescence, 7 a phenotype that is further aggravated upon concomitant deletion of either p21 or p27. 7, 8 In particular, the regulation of HSC quiescence through p57 and p27 seems to take place upstream of the retinoblastoma protein (Rb) family. 8 The regulation of CKI occurs mainly at the post-translational level through control of protein stability. This mechanism has been best elucidated for p27, an established tumor suppressor in hematological malignancies and solid cancers. 9,10 p27 degradation is mainly controlled by the activity of the E3 ubiquitin ligase complex SCF Skp2 . 9, 11 For efficient ubiquitylation of phosphorylated p27 SCF Skp2 requires the presence of a small protein, the Cdk subunit 1 (Cks1). 12 In addition to the regulation of p27 protein levels, SCF Skp2 has further been associated with the posttranslational regulation of other CKI including p21, 13 p57 14 and the Rb family member p130. 15 A unique feature of SCF Skp2 within the SCF-type ligase family is the additional presence of the Cks1 adapter protein. Skp2 knockout models have demonstrated a hematopoietic phenotype. 16, 17 Considering Cks1 shows features that are not necessarily connected to this adaptor function, in particular, regulation of Cdk1 18 and Cdk2 19 activity, Cks1 could be involved in HSC regulation through the SCF Skp2 complex, but also through other mechanisms. Here we studied the hematopoiesis in mice deficient for Cks1. We demonstrate that loss of Cks1 in HSC/HPC results in upregulated CKI levels, disturbed recruitment of HSC into the cell cycle during engraftment, and impaired response to myeloablation. In addition, we find that Cks1 is upregulated by Bcr-Abl, mediating Bcr-Abl-induced clonogenic activity and suppressed upon imatinib therapy in CML. Our data thus establish Cks1 as a crucial regulator of the levels of CKI in HSC/HPC during hematopoietic stress responses.
RESULTS

Loss of Cks1 expression results in accumulation of SCF Skp2 substrates
The ubiquitin ligase complex SCF Skp2 is a prominent mediator for the degradation of cell cycle regulatory proteins. 4, 20 Whether Cks1 is required as an adaptor of the SCF Skp2 complex in hematopoietic stem and progenitor cells (HSPC) has, so far, not been explored. We initially analysed expression of Cks1 and several SCF Skp2 target proteins in hematopoietic cells from the bone marrow (BM) of Cks1 −/− mice and their wild type (wt) littermates. We found stronger expression of Cks1 protein in the lineage-negative, cKitpositive (Lin − Kit+) fraction of BM that is enriched for HSPCs as compared with the fraction of differentiated cells expressing lineage markers (Lin+) (Figure 1a ). The high Cks1 expression in the fraction of HSPCs correlated with increased levels of Cks1 transcripts particularly in the HSC-enriched fraction that are Lin − Kit+Sca-1+CD34 − (Supplementary Figure S1 ). We then studied whether Cks1 deficiency affected some selected known targets of the SCF Skp2 ubiquitin ligase. We found a significant accumulation of all three CIP/KIP family members, p21, p27 and p57, and also of another known SCF Skp2 target, p130, in Cks1 −/− hematopoietic cells as compared with their Cks1 wt counterparts. Interestingly, the most pronounced accumulation of SCF Skp2 targets was detected in the earliest CD150+CD34 − Lin − Sca-1+ Kit+ (LSK) HSC-containing population, 21 as detected by intracellular protein staining (Figures 1b and c) . Taken together, we show that Cks1 is highly expressed in HSPCs, and its loss results in a pronounced accumulation of CKI, which are prominent SCF Skp2 targets. As the analyzed substrates of SCF Skp2 /Cks1 have been identified as important regulators of HSPC homeostasis [6] [7] [8] 22 (reviewed in Pietras et al. 1 ), our data suggest a prominent function for Cks1 in the control of CKI protein levels and in cell cycle control, particularly in CD150+CD34 − LSKs.
Ig control
Loss of Cks1 leads to accumulation of early HSCs and compromised hematopoietic colony formation Cks1 − / − mice display 10-20% body size reduction starting from embryonic day 13.5 (E13.5) until adulthood. 12 We observed a strong reduction of the total cell numbers in the fetal liver of E14 embryo and the BM of 8-12-week-old Cks1 − / − mice compared with their wt (Cks1 +/+ ) counterparts (Figure 2a ). Compared with the 10-20% reduction in body size, 12, 19 the distinct reduction in fetal liver (36.0%) and BM (37.7%) cells suggests possible alterations in early hematopoiesis. However, the populations of mature blood cells and the bone structure of Cks1 − / − mice were unchanged, indicating unaltered differentiation of Cks1-deficient HSCs ( Supplementary Figures S2b and c) . Flow cytometric analysis of Cks1 − / − and wt BM cells revealed unchanged percentages of myeloid progenitors (MPs) and Lin − Sca-1+Kit+ HSC (LSKs) upon Cks1 loss (Figure 2b ), but decreased absolute number of MPs (Supplementary Figure S3 ). The percentages of the most immature HSC subsets, the CD34 − and CD150+CD34 − LSKs 21, 23 were, on the other hand, significantly increased in Cks1 − / − mice compared with their wt littermates (Figures 2c and d (Supplementary Figure S3c ). Despite the increase in earliest HSCcontaining cell fractions, we identified a reduction of the frequency of HPCs, as exemplified by colony-forming cells (CFCs) in fetal liver (E14) and BM of Cks1 − / − mice compared with their wt littermates (Figure 2e ), suggesting that Cks1-deficient HPCs exhibit a growth or a survival defect. These data indicate that Cks1 is involved in the regulation of HSCs and HPCs, and that Cks1 is an indispensable component of the SCF Skp2 complex.
Cks1 protects HPC from apoptosis
The capacity of HPCs to form CFCs is dependent on cell proliferation, but also on the susceptibility of HPCs to apoptosis. To understand why we observe increased numbers of CD34 − CD150+ LSKs, but reduced HPC activity, we investigated the survival of cytokine-stimulated HSPCs and their apoptosis after cytokine withdrawal in vitro ( Figure 3a ). We observed a significantly lower fold increase in total cell numbers, in particular in MPs and LSKs cultured from Cks1 − / − mice during the cytokinestimulated culture period ( Figure 3b ). After cytokine deprivation, we found increased apoptosis in the Lin − fraction of Cks1deficient BM, especially in Lin − cells and MPs but not in LSKs (Figures 3c and d, Supplementary Figure S4 ). These findings suggest that in LSKs, Cks1 loss is responsible for the decreased cell proliferation, but does not affect apoptosis, whereas in MPs, Cks1 is also required for the survival of HPCs, which may explain the reduced frequency of CFC and number of MPs at steady state (Figure 2e and Supplementary Figure S3b , respectively). Our results thus indicate that Cks1 protects HPCs from cell death and regulates proliferation of both HSCs and HPCs.
Cks1 is a mediator of the hematopoietic stress response Our previous experiments indicate that Cks1 regulates cell cycling behavior. Indeed, we observe a significant decrease of Bromodeoxyuridine (BrdU) incorporation in S phase of Lin − cells from Cks1 − / − mice compared with their wt littermates (Figures 4a and b ). Since S phase entry and/or progression is important for proliferation in a regenerative response, this finding suggests a role of Cks1 in hematopoietic regeneration after stress. To analyze the role of Cks1 upon hematopoietic stress, we treated Cks1 − / − and their wt littermates with 5-fluorouracil (5-FU) ( Figure 4c ). 5-FU targets actively cycling cells in S phase, thus recruiting nondividing HSCs into the cell cycle. 24 We found that 5 days after 5-FU treatment, peripheral blood cell numbers and blood cell composition in Cks1 − / − mice were unchanged (Supplementary Figure S5a) . Consistent with the steady state results (Figure 2e ), the total number of CFCs was significantly reduced in the BM of 5-FU-treated Cks1 − / − mice as compared with wt counterparts (Supplementary Figure S5b) . To estimate the recovery of HSPCs after 5-FU-induced cytotoxic stress, we calculated the ratio of d0 (prior to 5-FU treatment) and d6 (after 5-FU treatment). Although the total cell numbers in the BM and absolute numbers of MPs was unchanged in the Cks1 − / − BM (Supplementary Figure S5c actively cycling cell populations. Thus, it is possible that in Cks1 − / − mice self-renewal is preserved more in the quiescent fraction of cells than in wt cells. To study this hypothesis in vitro, we analyzed sorted CD34 − CD150+ LSK cells (Figure 2c ) from the BM of Cks1 − / − and wt mice for self-renewal in a replating assay ( Figure 5a ). We found that wt cells lost their clonogenic activity after three passages. Cks1-deficient cells performed similar to wt cells in the first two replating rounds. However, Cks1 − / − cells retained replating capacity much longer, and formed colonies up to the sixth round of replating (Figure 5b ,c), indicating that loss of Cks1 selects a cell population with longer replating capacity in vitro. We next studied the quality of Cks1-deficient HSCs in vivo and performed serial transplantation experiments with sorted CD34 − CD150+ LSKs from the BM of Cks1 − / − and wt littermates into lethally irradiated wt recipients (Figure 6a ). Consistent with a slower rate of cell cycling under stress conditions (Figures 4d and f) and the slightly increased sensitivity to apoptosis of mature cells (Figures 3c and d) , the percentage of Cks1-deficient donor cells engrafting in primary recipients (1°) was decreased ( Figure 6b ). This culminated in a significant lower number of the donor-derived Cks1 − / − MPs (Figure 6c ). In accordance with a longer preservation of the G0/G1 state in Cks1-deficient cells (Figures 4b and f ), the proportion of regenerated Cks1 − / − donorderived CD150+ LSK was increased (Figures 6c and d) . These results indicate that Cks1 regulates the regeneration of the HSC pool as well as overall engraftment.
To find out whether the regenerated Cks1 − / − HSCs show the same increase in self-renewal of the earliest CD150+ LSK population, we performed secondary transplantations of sorted donor-derived CD150+ (wt or Cks1 − / − ) LSK cells. This experiment showed that again the regenerated fraction of CD150+ LSK cells was larger in secondary regenerated Cks1 − / − donor cells than in donor cells from wt littermates (Figure 6e ). More importantly, we found that BrdU incorporation was decreased in the Cks1 − / − donor-derived LSK populations (Figures 6f and g) , demonstrating that regenerated Cks1 − / − HSC enter S phase at a slower rate. Thus, our data reveal that Cks1 deficiency preserves HSCs through slowing entry into the S phase of the cell cycle.
Cks1 is upregulated in CML and is a mediator of Bcr − Abl-induced clonogenic activity Considering that uncontrolled HSPC regenerative activity and blocked apoptosis are hallmarks of the prototypic HSC disorder Bcr-Abl+ CML, [25] [26] [27] we assessed the expression of Cks1 (CKS1B in humans) transcript in CML patient samples. CKS1B transcript levels were elevated in untreated CML (Figure 7a ) and in CML versus normal control cells (Figures 7b and c) 28 (GEO accession: GSE24739). When mining publicly available gene expression data for a CML patient cohort treated with imatinib, 29 we found a significant suppression of CKS1B transcript levels upon imatinib treatment (Figures 7d and e ), whereas activation of Bcr-Abl kinase activity led to an increase in Cks1 transcript and protein (Figure 7f , Supplementary Figure S6a ). The treatment of cells ectopically over-expressing Bcr-Abl with the kinase inhibitor imatinib resulted in a reduction of Cks1 protein level (Figure 7g , Supplementary Figure S6b ). Similar to nontransformed Cks1 − / − cells (Figure 2e ), Bcr-Abl+ cells also showed reduced frequency of CFCs (Figure 7h ). Thus, Cks1 expression is associated with Bcr-Abl activity in the stem cell disorder CML, and Cks1 is a mediator of Bcr-Abl-induced cytokine-independent clonogenic activity.
DISCUSSION
In this study we provide genetic in vitro and in vivo evidence that the rate-limiting adaptor protein of the SCF Skp2 ubiquitin ligase, Cks1, is a critical mediator of the activity of the normal and malignant HSPC pool. Several substrates of SCF Skp2 /Cks1, in particular the Cdk inhibitors [6] [7] [8] 22 and p130 together with the other Rb family members 30 have been identified as important regulators of HSPC homeostasis by means of gene knockout studies (reviewed in Pietras et al. 1 ). We demonstrate that p21, p27, p57 and p130 accumulate most strongly in the CD150+ LSK population in Cks1 − / − mice and that Cks1 deficiency results in decelerated HSC cycling and increased quiescence. Our findings partly overlap with reports of Skp2 − / − mice, 16, 17 which indicate that both Skp2 and Cks1 are required for correct function of this complex in the regulation of hematopoiesis. Our results are opposite to the effects observed upon p57 7 or combined p57/ p27 8 loss, that is increased HSC cycling and HSC exhaustion. In line, the CKI p21, p27 and p57 accumulate most strongly in the CD150+ LSK population, demonstrating that Cks1 is a determining factor in the amassing of these proteins which maintain the selfrenewing population of HSC. Together with published reports, 1, 31 our findings clearly indicate that the control of CKIs and p130 by the SCF Skp2 /Cks1 complex is of paramount importance for maintenance of normal and malignant HSC self-renewal and quiescence. SCF-type ubiquitin ligase complexes use a family of F-box proteins as substrate adapters to mediate the degradation of a large number of regulatory proteins involved in diverse processes. The coordinate expression of such substrate adaptors is therefore of utmost importance. 20, 32 In the case of SCF Skp2 , Cks1 adds an additional level of substrate specificity, 12, 20 implying that the regulation of Cks1 transcript and protein levels should be tight. As the level of Cks1 is a critical determinant in the balance between HSC quiescence and activation, one would predict that decreased Cks1 would favor quiescence, and increased Cks1 expression promotes HSC activation. Thus, it would be likely that Cks1 levels were increased in cancers. Indeed, we find that Cks1 levels are increased in patients with Bcr-Abl+ CML. In addition, in various other malignancies elevated levels of Cks1 transcript and protein are associated with high proliferation and also poor Cks1 controls the hematopoietic stem cell pool V Tomiatti et al prognosis, 20, 33, 34 indicating that induction of Cks1 overexpression is a general mechanism in oncogenic transformation, which contributes to aggressive disease and possibly treatment resistance. Indeed, Myc overexpression or activation that leads to induction of Cks1 expression 35 results in suppression of p27 levels and resistance to the Abl inhibitor imatinib in CML. 36 Another Myc-regulated protein, Blk, was shown to act as tumor suppressor by upregulating p27 through downregulation of Skp2. 37 Further data that link SCF Skp2 to fate decisions in cancer-initiating cells come from successful pharmacological inactivation of Skp2 as a novel therapeutic means. 38 Since not every Skp2-mediated substrate recognition requires the presence of Cks1, 20 it is currently not clear whether for some cancer types the isolate inhibition of the Cks1-Skp2 physical interaction could be a more specific and/or less toxic approach as compared to ubiquitous SCF Skp2 inhibition. In this context it also has to be noted that loss of Cks1, but not loss of Skp2, results in a significant delay in tumorigenesis in the same Myc lymphoma model, 35, 39 and that Cks1 has cell cycle regulatory functions independent of p27 suppression. 19 We also found that under cell culture conditions which stimulate HSC to be recruited into the cell cycle, Cks1 deficiency promotes cell death of MPs upon growth factor withdrawal. One possible explanation could be the accumulation of p27, as p27 Cks1 controls the hematopoietic stem cell pool V Tomiatti et al overexpression has been shown to result in apoptosis. 40 Accumulation of the CKI p27 in Skp2-deficient animals has also been associated with an pRb/E2F1-dependent proliferation/ apoptosis switch. 41, 42 Whether similar mechanisms of a p27dependent pro-apoptotic switch also operate in Cks1 − / − HPC remains to be studied. As most of the assays we performed depend on detection of MP-derived cells, increased apoptosis in this population could explain why, despite a higher rate of selfrenewal of earlier cells, we find less colony activity upon Cks1 loss.
Since the mechanisms regulating cell death in actively cycling HPC are as yet unclear, and detecting rare cell fractions undergoing apoptosis is compromised by rapid clearance in vivo, only complex genetic in vivo studies involving the respective mutant mouse strains could resolve this issue.
In this study we identify Cks1 as an essential regulator of HSC fate operating upstream of the cell cycle inhibitors p27, p21 and p57. Our results show that Cks1 deficiency allows accumulation of the most immature CD150+ LSK HSC compartment in G0 of the cell cycle. Under stress conditions, HSC are activated normally, but more differentiated cell HPC progeny is sensitive to apoptosis, resulting in less clonogenic activity, delayed regeneration after 5-FU treatment and decreased engraftment of irradiated recipients. A model summarizing our results is depicted in Supplementary  Figure S7 . Although Cks1 also participates in regulation of Cdk activity, the finding that Cks1 loss closely resembles the Skp2 deletion phenotype indicates that both Skp2 and Cks1 are required for functional SCF Skp2 -mediated ubiquitylation of CKI in HSPC. In CML, Cks1 is overexpressed and Cks1 loss results in impaired oncogene-induced growth factor independence. We therefore propose Cks1 as a central intermediate for normal and oncogene-induced cell cycle regulation in hematopoiesis, and as a therapeutic target in hematologic malignancies.
MATERIALS AND METHODS Mice
Cks1 − / − mice 12 were backcrossed on the (129S2 × C57BL/6.J)F1 (129B6) background. In transplantation experiments, the F1 generation of 129S2 × C57BL/6. B6.SJL-Ptprca Pep3b/BoyJ (129Ly5.1) mice were used as recipients. Mice were kept in microisolators under SPF conditions according to FELASA recommendations.
Tissue and organ samples
Blood samples were collected into 1.2 ml heparinised tubes (Sarstedt AG, Nümbrecht, Germany). Blood cells were counted on a Scil Vet ABC (ScilAnimal Care, Viernheim, Germany). BM cells were flushed from femurs and tibias with HF2+ buffer (Hank's balanced salt solution, supplemented with 2% fetal calf serum, 10 mM HEPES buffer and antibiotics). Spleens were passed through 70 mm nylon Cell Strainer (BD Biosciences, Heidelberg, Germany). White blood cells were counted after red cell lysis with ammonium chloride solution (Stemcell Technologies, Vancouver, BC, Canada). Viable cells were counted using trypan blue (Life Technologies, Carlsbad, CA, USA) in a Neubauer hemocytometer.
Five micrometer (μm) thick paraffin bone sections were prepared from decalcified bone samples dissected from 10-12-week-old animals. Hematoxilin-eosin stain was performed as described previously. 19 All animal experiments were performed in accordance with the regional animal ethics committee approvals.
Flow cytometry and cell sorting
Cell suspensions were stained with antibodies for surface antigens ( Supplementary Table S1 ) in 1X phosphate buffered saline (PAA, GE healthcare life sciences, Freiburg, Germany), 0.5% bovine serum albumin (Roth, Karlsruhe, Germany) buffer for 15 min on ice in the dark. Cells viability was assessed by propidium iodide stain (BioLegend, San Diego, CA, USA). For the intracellular staining, BM cells from adult mice were lineage depleted, stained for surface markers, permeabilized, fixed and stained for intracellular antigens ( Supplementary Table S2 ) using Fix&Perm cell permeabilization reagents (Life Technologies). Fluorescence-activated cell sorting analysis was performed on a CyAn ADP Lx 9 (Beckman Coulter, Munich, Germany) flow cytometer. Fluorescence-activated cell sorting data were analyzed using the FlowJo software (TreeStar Inc., Ashland, OR, USA).
Cell populations were sorted on the MoFlo Legacy 14-color cell sorter (Beckman Coulter) supplied with Summit 4.3 software (Beckman Coulter).
Real-time PCR and gene expression analysis
cDNA from patient samples and cultured cells was reverse transcribed using the Omniscript RT Kit on mRNA isolated with the RNeasy Mini Kit (both from Qiagen, Hilden, Germany). From the sorted cells, mRNA was isolated with Dynabeads mRNA DIRECT Micro Kit (Life technologies) as described by the manufacturer. cDNA was amplified with Omniscript RT kit (Qiagen) as described by the manufacturer. Real-time PCRs were performed using the StepOnePlus Real Time System (Life Technologies) with the Power SYBR Green PCR Master Mix (Applied Biosystems, Life Technologies) for cDNA samples from sorted cells and the CYBR Green PCR Master Mix (Life Technologies) for banked samples from CML patients and cell culture. Real-time PCR data was analyzed using the StepOne Real-Time PCR System (Life Technologies). Transcript expression is presented as a relative value (2ΔCt method) compared with the expression levels of housekeeping genes Rpl13a and Ubiquitin. Primer sequences are shown in Supplementary Table S3 .
Public available gene expression data (GSE24739) 28 and (GSE12211) 29 was downloaded from gene expression omnibus website (http://www. ncbi.nlm.nih.gov/geo/) and analyzed using R-studio version 0.97.551 (Boston, MA, USA).
Immunoblotting
Lineage-depleted (lineage cell depletion kit) and enriched for Kit BM cells were sorted using a magnetic beads separation Kit (Miltenyi Biotec, Gladbach, Germany) according to the manufacturer's instructions. The sorted cells were lysed and immunoblotting was performed with the antibodies listed in Supplementary Table S2b as described previously. 19 In vitro cell culture and CFC assays Lineage-deleted BM cells were cultured in medium (MyeloCult 5300, STEMCELL Technologies, Vancouver, BC, Canada) supplemented with stem cell factor (100 ng/ml), thrombopoietin (20 ng/ml) and Flt3 Ligand (50 ng/ ml) (all from R&D Systems, Minneapolis, MN, USA) at 37°C with 5% CO 2 . After cytokine withdrawal cells were collected, fixed with 4% paraformaldehyde in 1X phosphate buffered saline and stained with Annexin V-FITC (BioLegend) and propidium iodide (BioLegend).
CFC assay was performed in growth factor-supplemented semi-solid medium (MethoCult M3434, Stem Cell Technologies) at 37°C with 5% CO 2 for 12 days. Colonies formed were counted under a light microscope using standard criteria.
BM infection and transplantation
In transplantation experiments the CD45 congenic system was used to distinguish donor from recipient cells. 129Ly5.1 recipient mice were lethally irradiated with 9Gy and received donor cells via the tail vein on the same day, as described previously. 43 After 16 weeks, mice were sacrificed and the BM, spleen and blood cells were analyzed. Mice with engraftment over 1% of myeloid and 1% lymphoid lineages were defined as positive mice.
In serial transplantation experiments, primary recipients (1°) were repopulated with 300 CD150+ LSKs sorted from the BM of Cks1+/+ or Cks1 − / − mice and helper cells (5x10 5 wt-derived spleen cells and 1 × 10 5 wt-derived BM cells). 16 weeks post-transplantation 300 donor-derived (Ly5.2+) CD150+ LSK were sorted from the 1°recipients (129Ly5.1: positive for both Ly5.1 and Ly5.2) and were transplanted into lethally irradiated 129Ly5.1 mice (secondary recipients (2°)) with helper cells. After 16 weeks, 2°mice were injected intraperitoneally with 50 μg/g body weight BrdU. 12 h after BrdU exposure (overnight), mice were sacrificed and BM, spleen and blood cells were analyzed.
To generate Bcr-Abl-expressing cells, retrovirus was obtained through transfection of Phoenix E cells with MSCV-IRES-Bcr-Abl-p210-GFP 44 using lipofectamine 2000 (Invitrogen). To facilitate transfection of cells, mice were treated with 150 mg/kg 5-FU 4 days prior infection. 45 Cks1 controls the hematopoietic stem cell pool V Tomiatti et al Cell cycle analysis and 5-FU treatment.
For cell cycle analysis, animals were injected intraperitoneally with 50 μg/g body weight of BrdU. After 12 h, BM cells were flushed and stained with surface markers prior to BrdU detection with a BrdU labeling kit as described by the manufacturer (BD Biosciences).
To induce hematopoietic stress, 5-FU (150 μg/g body weight in HF2+, Sigma-Aldrich, St Louis, MO, USA) was injected intraperitoneally on day 0. Five days later mice were injected intraperitoneally with BrdU and analyzed by flow cytometry the next day (d6).
Statistical analysis
Statistical analyses were performed using the statistical functions of Excel (Microsoft, Redmond, WA, USA), GraphPad Prism (GraphPad Software, La Jolla, CA, USA) and R-studio version 0.97.551. The bars shown represent the standard error of the mean (s.e.m.). Student's t-tests were performed to test the hypotheses whether experiments performed with wt (Cks1 +/+ ) cells or mice differed from those performed with Cks1 − / − cells or mice. In experiments with more than three groups analysis of variance testing was used to determine significant differences. Only P-values o0.05 were considered statistically significant.
